The $350 million sale of BioReliance by Avista Capital Partners to Sigma-Aldrich (NASDAQ: SIAL) has been granted early termination by the FTC. The transaction was announced earlier this month and is expected to close this quarter. BioReliance provides biopharmaceutical testing services and was acquired by Avista in 2007.
© 2020 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.